Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FURIN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FURIN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FURIN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FURIN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FURIN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FURIN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FURIN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:0031330113 | Thyroid | PTC | negative regulation of cellular catabolic process | 131/5968 | 262/18723 | 6.63e-10 | 2.03e-08 | 131 |
GO:007156019 | Thyroid | PTC | cellular response to transforming growth factor beta stimulus | 126/5968 | 250/18723 | 7.34e-10 | 2.19e-08 | 126 |
GO:0009895113 | Thyroid | PTC | negative regulation of catabolic process | 154/5968 | 320/18723 | 7.77e-10 | 2.31e-08 | 154 |
GO:000717919 | Thyroid | PTC | transforming growth factor beta receptor signaling pathway | 104/5968 | 198/18723 | 1.20e-09 | 3.47e-08 | 104 |
GO:0042177113 | Thyroid | PTC | negative regulation of protein catabolic process | 66/5968 | 121/18723 | 1.97e-07 | 3.54e-06 | 66 |
GO:000717819 | Thyroid | PTC | transmembrane receptor protein serine/threonine kinase signaling pathway | 156/5968 | 355/18723 | 1.02e-06 | 1.51e-05 | 156 |
GO:00336197 | Thyroid | PTC | membrane protein proteolysis | 36/5968 | 57/18723 | 1.16e-06 | 1.69e-05 | 36 |
GO:005160420 | Thyroid | PTC | protein maturation | 132/5968 | 294/18723 | 1.71e-06 | 2.39e-05 | 132 |
GO:0052547113 | Thyroid | PTC | regulation of peptidase activity | 191/5968 | 461/18723 | 7.82e-06 | 9.02e-05 | 191 |
GO:1903363112 | Thyroid | PTC | negative regulation of cellular protein catabolic process | 42/5968 | 75/18723 | 1.32e-05 | 1.43e-04 | 42 |
GO:000650913 | Thyroid | PTC | membrane protein ectodomain proteolysis | 27/5968 | 43/18723 | 2.96e-05 | 2.85e-04 | 27 |
GO:004311219 | Thyroid | PTC | receptor metabolic process | 77/5968 | 166/18723 | 6.21e-05 | 5.47e-04 | 77 |
GO:0052548113 | Thyroid | PTC | regulation of endopeptidase activity | 174/5968 | 432/18723 | 1.20e-04 | 9.55e-04 | 174 |
GO:007163512 | Thyroid | PTC | negative regulation of transforming growth factor beta production | 10/5968 | 12/18723 | 3.59e-04 | 2.44e-03 | 10 |
GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
GO:000646519 | Thyroid | PTC | signal peptide processing | 11/5968 | 14/18723 | 4.45e-04 | 2.95e-03 | 11 |
GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FURIN | SNV | Missense_Mutation | novel | c.2167N>T | p.Ala723Ser | p.A723S | P09958 | protein_coding | tolerated(0.14) | benign(0.247) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
FURIN | SNV | Missense_Mutation | novel | c.1492C>A | p.Arg498Ser | p.R498S | P09958 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
FURIN | SNV | Missense_Mutation | | c.356N>A | p.Pro119His | p.P119H | P09958 | protein_coding | tolerated(0.25) | possibly_damaging(0.572) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FURIN | SNV | Missense_Mutation | novel | c.1956N>C | p.Gln652His | p.Q652H | P09958 | protein_coding | tolerated(0.42) | benign(0.005) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | | c.1874N>T | p.Thr625Met | p.T625M | P09958 | protein_coding | tolerated(0.22) | benign(0.02) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | novel | c.245C>A | p.Pro82Gln | p.P82Q | P09958 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-OL-A6VR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FURIN | insertion | Frame_Shift_Ins | novel | c.547dupC | p.Gln183ProfsTer9 | p.Q183Pfs*9 | P09958 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FURIN | SNV | Missense_Mutation | novel | c.158N>A | p.Gly53Glu | p.G53E | P09958 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FURIN | SNV | Missense_Mutation | novel | c.958N>A | p.Ala320Thr | p.A320T | P09958 | protein_coding | tolerated(1) | benign(0.05) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FURIN | SNV | Missense_Mutation | novel | c.2167N>A | p.Ala723Thr | p.A723T | P09958 | protein_coding | tolerated(0.16) | benign(0.089) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166802 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, E | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 178103178 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, B | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166868 | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | | US9266828, C | | |
5045 | FURIN | ENZYME, PROTEASE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 252166858 | | |